<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epstein-Barr virus (EBV) is associated with a variety of human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Although the EBV-infected <z:mpath ids='MPATH_458'>normal</z:mpath> B cells in vitro and the EBV-carrying B cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> in immunodeficient patients express the full set of latent proteins (type III latency), the majority of EBV-associated <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> express the restricted type I (EBNA-1 only) or type II (EBNA-1 and LMPs) <z:mp ids='MP_0001799'>viral</z:mp> program </plain></SENT>
<SENT sid="2" pm="."><plain>The mechanisms responsible for these different latent <z:mp ids='MP_0001799'>viral</z:mp> gene expression patterns are only partially known </plain></SENT>
<SENT sid="3" pm="."><plain>IL-21 is a potent B cell activator and plasma cell differentiation-inducer cytokine produced by CD4(+) T cells </plain></SENT>
<SENT sid="4" pm="."><plain>We studied its effect on EBV-carrying B cells </plain></SENT>
<SENT sid="5" pm="."><plain>In type I Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) cell lines and in the conditional lymphoblastoid cell line (LCL) ER/EB2-5, IL-21 potently activated STAT3 and induced the expression of LMP-1, but not EBNA-2 </plain></SENT>
<SENT sid="6" pm="."><plain>The IL-21-treated type I Jijoye M13 <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> line ceased to proliferate, and this was paralleled by the induction of IRF4 and the down-regulation of BCL6 expression </plain></SENT>
<SENT sid="7" pm="."><plain>In the type III LCLs and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> lines, IL-21 repressed the C-promoter-derived and LMP-2A <z:chebi fb="2" ids="33699">mRNAs</z:chebi>, whereas it up-regulated the expression of LMP-1 mRNAs </plain></SENT>
<SENT sid="8" pm="."><plain>The IL-21-treated type III cells underwent plasma cell differentiation with the induction of Blimp-1, and high levels of Ig and Oct-2 </plain></SENT>
<SENT sid="9" pm="."><plain>IL-21 might be involved in the EBNA-2-independent expression of LMP-1 in EBV-carrying type II cells </plain></SENT>
<SENT sid="10" pm="."><plain>In light of the fact that IL-21 is already in clinical trials for the treatment of <z:e sem="disease" ids="C0346429" disease_type="Neoplastic Process" abbrv="">multiple malignancies</z:e>, the in vivo modulation of EBV gene expression by IL-21 might have therapeutic benefits for the EBV-carrying <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
</text></document>